Drug intelligence / Profile preview

TDM-105795

Development stage: Phase 2
Lead developer: TechnoDerma Medicines
Modality: Small Molecules
Administration: Topical

Overview

TDM-105795 is a topical small molecule drug candidate developed for the treatment of androgenetic alopecia (AGA). It acts as a potent thyromimetic, specifically functioning as a **thyroid hormone receptor agonist**. The drug is designed to activate dormant hair follicle stem cells and induce the anagen (growth) phase in hair follicles, thereby promoting hair regrowth. Clinical studies have shown that TDM-105795 increases non-vellus target area hair count in men with AGA and demonstrates minimal systemic absorption when applied topically, resulting in a favorable safety profile. The developer aims to offer improved efficacy and safety compared to existing treatments for androgenetic alopecia[1][2][3][5][6][8].

Other names: TDM 105795TDM105795TDM-105795

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on TDM-105795.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TDM-105795.

Explore the full profile